People with ultra-high-risk multiple myeloma may respond poorly to treatment, relapse quickly after they have had chemotherapy, and have a poor prognosis. However, new treatment options such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody approaches are showing promise for these patients, says Gareth J. Morgan, MD, PhD, professor in the Department of Medicine at NYU Grossman School of Medicine and director of multiple myeloma research at NYU Langone Health’s Perlmutter Cancer Center.
“The results we see in relapsed/refractory patients with these agents really suggest they’re going to be game changers for ultra-high-risk myeloma,” Dr. Morgan says. “And it’s making me very excited for the change that it’s going to bring about for patients.”
Watch and read more from Patient Power.